Is GLP-1 the Same as Mounjaro? Not Quite — Here's the Real Difference

The misconception: 'GLP-1' and 'Mounjaro' are interchangeable labels

A common assumption is that Mounjaro is simply a brand name for a GLP-1 drug, in the same way Wegovy is. That framing is understandable (Mounjaro is widely discussed alongside Wegovy in the same breath) but it is not quite right. GLP-1 receptor agonists (such as semaglutide) work by mimicking one hormone. Tirzepatide, the active ingredient in Mounjaro, mimics two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

GIP is a second gut hormone. When both receptors are activated together, the appetite-suppressing and metabolic effects are additive in a way that a single-pathway drug cannot replicate. So calling Mounjaro a GLP-1 drug is a bit like calling a car with two engines a car with one engine. Technically part of the picture; practically misleading.

If you want to read more about how tirzepatide's dual mechanism compares with semaglutide's single pathway, our overview of Mounjaro and the GLP-1 receptor covers that ground in detail.

The broader takeaway: when you see "GLP-1 treatment" used as a catch-all, check which drug is actually being discussed. The phrase covers a family of medicines, not a single product.

What Mounjaro actually is, and how its two-receptor action differs from semaglutide

Mounjaro is the UK brand name for tirzepatide, manufactured by Eli Lilly. It comes as a once-weekly subcutaneous injection via a pre-filled KwikPen, with treatment starting at 2.5 mg. The tirzepatide page on our site covers the mechanism and licensed uses in full.

Its dual-agonist design is what sets it apart within the GLP-1 drug family. In the SURMOUNT-1 trial, participants using tirzepatide achieved average body-weight reductions of around 20–21% at the highest dose over 72 weeks, as reported in the New England Journal of Medicine. That is a larger average reduction than semaglutide 2.4 mg produced in its own pivotal trial, and the SURMOUNT-5 head-to-head comparison confirmed tirzepatide's greater average weight loss directly.

The question of whether GLP-1 is the same as tirzepatide has a clean answer: no. Tirzepatide goes beyond the GLP-1 pathway. If you are deciding between tirzepatide and a semaglutide-based option, our Mounjaro information page and the weight-loss treatment overview explain the licensed indications and eligibility side by side.

Worth checking: the GPhC register lets you confirm any online pharmacy's registration in under a minute at pharmacyregulation.org/registers. It is a quick habit when you are researching treatment online.

Who can access Mounjaro in the UK, and what clinical assessment covers

Mounjaro is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. NICE's appraisal of tirzepatide, TA1026, sets NHS eligibility criteria (which are stricter than the licensed criteria) but private prescribing follows the licensed indications, subject to a prescriber's full assessment.

BMI is a starting point, not a guarantee. A prescriber considers your medical history, current medicines, any contraindications and your weight-related health picture before approving treatment. Mounjaro is not recommended during pregnancy, while breastfeeding, or for those actively trying to conceive, and it is not licensed for under-18s.

On the cost side, private Mounjaro pricing has shifted considerably since Eli Lilly raised its UK list price in September 2025, typical private prices now range roughly £149–£375 per month depending on dose and provider, as widely reported. If pricing is a key part of your decision, our Mounjaro cost page gives honest context on what those figures include (and often what they don't).

Other medicines are sometimes discussed in the same breath as Mounjaro. If you are curious whether a specific formulation is genuinely the same compound, this page confirms the tirzepatide/Mounjaro relationship plainly.

Side effects and what single-pathway vs dual-pathway means in practice

Both single-pathway GLP-1 drugs and tirzepatide share a broadly similar side-effect profile because they both activate GLP-1 receptors. Nausea, loose stools, constipation, indigestion, fatigue and mild headache are the most commonly reported effects across the class. Symptoms tend to peak after a new pen or a dose step, then ease as the body adjusts, usually within a few days to a couple of weeks. The NHS tirzepatide medicines page lists the full side-effect picture clearly.

Because Mounjaro also activates GIP receptors, researchers expected a different tolerability profile. In practice, the GI side-effect pattern is similar to semaglutide, though individual responses vary. Any severe or persistent abdominal pain that radiates to the back needs urgent medical assessment, this applies to all medicines in this class.

Women taking oral contraceptives should use an additional non-oral method of contraception for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, as absorption of the pill may be affected. There is no equivalent guidance for semaglutide on this point.

If you have questions about interactions with other medicines you take alongside Mounjaro, our atorvastatin and Mounjaro page is one example of the specific guidance our prescribers work through. Our clinical team, led by our Independent Prescriber, reviews every consultation personally before any treatment is approved.